Ka Kit Wong

Ka Kit Wong

Auto-generated profile, based on publicly available information

Ka Kit Wong

Division of Nuclear Medicine, Department of Radiology, University of Michigan, Ann Arbor, Michigan

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 November 2018 in Clinical Diabetes and Endocrinology
Verified
Journal Article
Open access
PDF file
KWKa Kit Wong
Ka Kit Wong
BSBarry L. Shulkin
Barry L. Shulkin
MGMilton D. Gross
Milton D. Gross
AAAnca M. Avram
Anca M. Avram
To evaluate the success rate of therapeutic administration of a single calculated 131I activity for eliminating hyperthyroidism due to Graves’ disease. Patients with Graves’ hyperthyroidism underwent pinhole thyroid imaging, 24-h radioactive iodine uptake (RAIU) measurements and clinical examination and received a calculated 131I activity of 0.2 mCi per estimated gram of thyroid tissue, adjusted for the 24-h RAIU. The goal of RAI treatment was to achieve hypothyroidism within 3–6 months of 131I administration. Response to RAI therapy was assessed at 7 weeks and 3 months by clinical and biochemical follow-up. The study included 316 hyperthyroid patients with Graves’ disease (F238:M78, mean age 42.1 ± 16 y, 4–94). 179 patients (56.6%) had no prior therapeutic intervention (treatment-naive patients), whereas 6 patients had prior thyroid surgery, and 131 (41.5%) had been treated with anti-thyroid medications. The mean estimated thyroid gland size was 50.2 g ± 18, range 15–100. Mean RAIU was 0.57 ± 0.17 (normal 0.07–0.30). RAI doses ranged from 5 to 70 mCi (mean dose = 18.1 mCi). Successful treatment of hyperthyroidism at our institution was obtained after a single therapeutic 131-I activity administration in 295 of 316 (93.3%) patients. Multivariate logistic regression analysis demonstrated that failure of 131I therapy was associated with previous PTU therapy (p < 0.001). The mean response time after successful RAI therapy was 110.2 days, with cumulative response of 25% at 61 days, 50% by 84 days and 75% by 118 days after radioiodine administration. The mean time to respond for those on prior PTU medications was 297 days compared to 116 days for those on MMI and 109 days for those not previously treated with antithyroid medications. In patients with persistent hyperthyroidism, failure of RAI therapy was documented in 16 patients (76.2%) within (less than) one year after 131I administration and in 5 patients (23.8%) more than one year after initial therapy, considered late failure. Successful 131I therapy for Graves’ hyperthyroidism with a single calculated dose can be achieved in the majority (> 90%) of patients, adjusting for the thyroid size and 24 h uptake measurement.

1 May 2008 in Clinical Nuclear Medicine
Verified
Journal Article
Closed access
KWKa Kit Wong
Ka Kit Wong
RBRichard Kj Brown
Richard Kj Brown
AAAnca M. Avram
Anca M. Avram
We report on a 55-year-old woman with suspected primary hyperparathyroidism who underwent dual phase Tc-99m sestamibi parathyroid imaging. Symmetric, patchy activity in the neck and shoulders was localized to low attenuation areas on integrated SPECT/CT and attributed to uptake in brown adipose tissue (BAT). Focal uptake in the anterior thorax on SPECT images, which potentially may have been misinterpreted as ectopic parathyroid tissue, was demonstrated on SPECT/CT as uptake in BAT. Recognition of this pattern on parathyroid SPECT/CT scintigraphy may avoid false positive reports. Our case provides further evidence that in addition to F-18 FDG, I-123 MIBG, and Tc-99m tetrofosmin, Tc-99m sestamibi may also accumulate in BAT.

1 September 2011 in Nuclear Medicine Communications
Verified
Journal Article
Closed access
KWKa Kit Wong
Ka Kit Wong
MAMohammad Arabi
Mohammad Arabi
IZImene Zerizer
Imene Zerizer
AAAdil Al-Nahhas
Adil Al-Nahhas
DRDomenico Rubello
Domenico Rubello
MGMilton D. Gross
Milton D. Gross
Positron emission tomography (PET) has seen an increasing clinical utilization in the last decade, such that it is now a standard oncology imaging modality. Its success is based on the detection of altered fluorine-18 fluorodeoxyglucose (18F-FDG) biodistribution, reflecting glucose transport/metabolism in malignant tumor tissues. Integrated PET/computed tomography cameras combine functional and anatomical information in a synergistic manner that improves diagnostic interpretation, and newer positron-emitting radiopharmaceuticals have been developed to expand the application of non-FDG PET imaging. The increasing use of cross-sectional imaging procedures has led to a more frequent detection of incidental adrenal masses. Although conventional imaging modalities such as computed tomography and MRI can characterize the majority of these lesions, 18F-FDG PET has been reported as a useful tool to distinguish benign from malignant etiologies in indeterminate adrenal masses. Although 18F-FDG PET has enjoyed success in staging a wide range of cancers, including detection of adrenal metastases and evaluation of adrenocortical carcinoma, it has had limited impact for the evaluation of neuroendocrine tumors. Positron-emitting amine precursor and somatostatin analogs have been validated in research settings to provide accurate imaging of enterochromaffin and chromaffin neuroendocrine tumors and medullary thyroid cancer. The aim of this review article is to provide an overview of the role of 18F-FDG and newer positron-emitting radiopharmaceuticals in the evaluation of adrenal and neuroendocrine tumors.

1 January 2016 in World Journal of Radiology
Verified
Journal Article
Open access
KWKa-Kit Wong
Ka-Kit Wong
AGArpit Gandhi
Arpit Gandhi
BVBenjamin L Viglianti
Benjamin L Viglianti
LFLorraine M Fig
Lorraine M Fig
DRDomenico Rubello
Domenico Rubello
MGMilton D Gross
Milton D Gross
Endocrine radionuclide scintigraphy with fusion single photon emission computed tomography/computed tomography

2 July 2022 in Current Opinion in Endocrinology, Diabetes and Obesity
Verified
Journal Article
Closed access
MRMolly E. Roseland
Molly E. Roseland
YDYuni K. Dewaraja
Yuni K. Dewaraja
KWKa Kit Wong
Ka Kit Wong
Purpose of review: Thyroid cancers are endocrine neoplasms with diverse gene expression and behavior, for which constantly evolving anatomic and functional imaging/theranostic agents have an essential role for diagnosis, staging, and treatment. Recent findings: To achieve definitive diagnosis, neck ultrasound and associated risk stratification systems, notably Thyroid Imaging Reporting and Data System (TI-RADS), allow improved thyroid nodule characterization and management guidance. Radioactive iodine-131 (RAI) has long played a role in management of differentiated thyroid cancer (DTC), with recent literature emphasizing its effectiveness for intermediate-high risk cancers, exploring use of dosimetry for personalized medicine, and potential for retreatment with RAI following tumor redifferentiation. Iodine-124 positron emission tomography/computed tomography (PET/CT) has promising application for DTC staging and dosimetry. F18-fluorodeoxyglucose (FDG) PET/CT is used for staging of high risk DTC and identification of noniodine-avid disease recurrences, with metabolic uptake consistently portending poor prognosis. Poorly differentiated and anaplastic thyroid cancers are best assessed with anatomic imaging and F18-FDG PET/ CT, though recent studies show a potential theranostic role for Ga68/Lu177-prostate-specific membrane antigen. Medullary thyroid cancers are evaluated with ultrasound, CT, magnetic resonance imaging, and various positron-emitting radiotracers for PET imaging (F18-DOPA, F18-FDG, and recently Ga68-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)–octreotate (DOTATATE)); the latter may enable treatment with Lu177-DOTATATE. Summary: Multidisciplinary collaboration is essential to streamline appropriate management, given the wide array of available imaging and new therapies for metabolic and genetically complex cancers.

10 June 2022 in Nuclear Medicine Communications
Verified
Journal Article
Closed access
KWKa Kit Wong
Ka Kit Wong
KFKirk A. Frey
Kirk A. Frey
JNJeremy Niedbala
Jeremy Niedbala
RKRavi K. Kaza
Ravi K. Kaza
FWFrancis P. Worden
Francis P. Worden
YDYuni K. Dewaraja
Yuni K. Dewaraja
Background: Our goal is to quantitatively compare radiotracer biodistributions within tumors and major normal organs on pretherapy 68Ga-DOTATATE PET to post-therapy 177Lu-DOTATATE single-photon emission computed tomography (SPECT) in patients receiving peptide receptor radionuclide therapy (PRRT). Methods: PET/CT at ~ 60 min postinjection of Ga-68 DOTATATE and research 177Lu-SPECT/CT imaging ~ at 4 h (SPECT1) and ~ 24 h (SPECT2) post-cycle#1 were available. Manual contours of lesions on baseline CT or MRI were applied to co-registered SPECT/CT and PET/CT followed by deep learning-based CT auto-segmentation of organs. Tumor-to-normal organ ratios (TNR) were calculated from standardized uptake values (SUV)mean and SUVpeak for tumor, and SUVmean for non-tumoral liver (nliver), spleen and kidney. Results: There were 90 lesons in 24 patients with progressive metastatic neuroendocrine tumor. The correlation between PET and SPECT SUV TNRs were poor/moderate: PET versus SPECT1 R2 = 0.19, 0.21, 0.29; PET versus SPECT2 R2 = 0.06, 0.16, 0.33 for TNRnliver,TNRspleen,TNRkidney, respectively. Across all patients, the average value of the TNR measured on PET was significantly lower than on SPECT at both time points (P < 0.001). Using SUVmean for tumor, average TNR values and 95% confidence intervals (CI) were PET: TNRnliver = 3.5 [CI: 3.0-3.9], TNRspleen = 1.3 [CI, 1.2-1.5], TNRkidney = 1.7 [CI: 1.6-1.9]; SPECT1: TNRnliver = 10 [CI: 8.2-11.7], TNRspleen = 2.9 [CI: 2.5-3.4], TNRkidney = 2.8 [CI: 2.3-3.3]; SPECT2: TNRnliver = 16.9 [CI: 14-19.9], TNRspleen = 3.6 [CI: 3-4.2], TNRkidney = 3.6 [CI: 3.0-4.2]. Comparison of PET and SPECT results in a sphere phantom study demonstrated that these differences are not attributed to imaging modality. Conclusions: Differences in TNR exist for the theranostic pair, with significantly higher SUV TNR on 177Lu SPECT compared with 68Ga PET. We postulate this phenomenon is due to temporal differences in DOTATATE uptake and internalization in tumor as compared to normal organs.